Ads
related to: list of tpa drugs for cancer- Recommended Dosing
Determine The Appropriate Dosing
For A Patient On IMFINZI.
- Clinical Study Results
View Clinical Study Results
& Efficacy Info For IMFINZI.
- Request Representative
Fill Out A Brief Form To Request
Assistance From A Representative.
- Safety Information
Learn About Safety & Efficacy
Information For IMFINZI.
- Recommended Dosing
Search results
Results From The WOW.Com Content Network
The tPA which was then secreted into the culture medium was isolated and collected for therapeutic use. For pharmaceutical purposes, tPA was the first pharmaceutical drug produced synthetically with the use of mammalian cells, specifically Chinese hamster ovarian cells . Recombinant tPA is commonly referred to as r-tPA and sold under multiple ...
Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter. [5]
Thus, TPA/PMA has been routinely used as an inducer for endogenous superoxide production. [5] TPA is also being studied as a drug in the treatment of hematologic cancer [citation needed] TPA has a specific use in cancer diagnostics as a B-cell specific mitogen in cytogenetic testing. Cells must be divided in a cytogenic test to view the ...
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
Plasminogen activator inhibitor-1 is a serine protease, synthesized by endothelial cells, that specifically inhibits tissue plasminogen activator (tPA) and urokinase (uPA). Tissue plasminogen activator and urokinase are the activators of plasminogen and result in the breakdown of blood clots ( fibrinolysis ).
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer